- Home
- PAYC vs BMRN Comparison
PAYC vs BMRN Comparison
Compare PAYC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- BMRN
- Stock Information
- Founded
- PAYC 1998
- BMRN 1996
- Country
- PAYC United States
- BMRN United States
- Employees
- PAYC N/A
- BMRN N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PAYC Technology
- BMRN Health Care
- Exchange
- PAYC Nasdaq
- BMRN Nasdaq
- Market Cap
- PAYC 13.1B
- BMRN 12.1B
- IPO Year
- PAYC 2014
- BMRN 1999
- Fundamental
- Price
- PAYC $251.28
- BMRN $60.50
- Analyst Decision
- PAYC Hold
- BMRN Buy
- Analyst Count
- PAYC 11
- BMRN 22
- Target Price
- PAYC $228.50
- BMRN $93.43
- AVG Volume (30 Days)
- PAYC 502.0K
- BMRN 1.6M
- Earning Date
- PAYC 05-07-2025
- BMRN 05-01-2025
- Dividend Yield
- PAYC 0.60%
- BMRN N/A
- EPS Growth
- PAYC N/A
- BMRN 152.82
- EPS
- PAYC 7.02
- BMRN 2.71
- Revenue
- PAYC $1,913,800,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- PAYC $9.65
- BMRN $12.27
- Revenue Next Year
- PAYC $9.59
- BMRN $9.86
- P/E Ratio
- PAYC $35.54
- BMRN $22.11
- Revenue Growth
- PAYC 9.87
- BMRN 19.36
- 52 Week Low
- PAYC $139.50
- BMRN $52.93
- 52 Week High
- PAYC $254.48
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- PAYC 73.34
- BMRN 43.22
- Support Level
- PAYC $223.36
- BMRN $58.74
- Resistance Level
- PAYC $254.48
- BMRN $61.26
- Average True Range (ATR)
- PAYC 6.78
- BMRN 1.91
- MACD
- PAYC 2.69
- BMRN 0.07
- Stochastic Oscillator
- PAYC 93.15
- BMRN 26.35
About PAYC Paycom Software Inc.
Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.